Immunocore Holdings plc was incorporated on January 7, 2021 under the laws of England and Wales. The company is a commercial-stage biotechnology company that creates and delivers transformative immunomodulatory drugs that fundamentally improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. Leveraging the Company's proprietary, flexible, off-the-shelf ImmTAX platform, the Company is developing a deep pipeline across multiple therapeutic areas, including clinical-stage programs in oncology and infectious diseases, advanced preclinical programs in autoimmune diseases, and early stage preclinical programs across three therapeutic areas. In 2022, the Company received FDA, European Commission and health authorities approval for the lead product KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.